Stanley J. Korsmeyer (March 10 1950 – January 21 2005) was an American cell biologist and professor of oncology who made seminal contributions to the understanding of programmed cell death (apoptosis).
Education and career
- Earned a B.S. in chemistry from the University of Wisconsin–Madison (1972).
- Completed a Ph.D. in biochemistry at the University of Wisconsin–Madison (1976), studying hemoglobin synthesis.
- Conducted post‑doctoral research in the laboratory of John C. Reed at the University of Michigan, focusing on cell death mechanisms.
- Joined the faculty of the University of Texas MD Anderson Cancer Center in 1985, where he served as Professor of Oncology and Director of the Center for Apoptosis Research.
Scientific contributions
- Discovered that the Bcl-2 gene, initially identified in B‑cell lymphoma, functions as an inhibitor of apoptosis, challenging the prevailing view that oncogenes primarily promote cell proliferation.
- Co‑identified the “Korsmeyer effect,” describing how overexpression of anti‑apoptotic Bcl‑2 can paradoxically promote tumor survival despite oncogenic stress.
- Helped elucidate the role of the Bcl-2 family of proteins in regulating mitochondrial pathways of cell death, establishing foundational concepts for targeted cancer therapies.
- Authored more than 150 peer‑reviewed publications, many of which are highly cited in the fields of cancer biology and immunology.
Awards and honors
- William B. Coley Award for Distinguished Research in Basic and Tumor Immunology (1998).
- Member of the American Association for Cancer Research (AACR) Academy (2001).
- Elected Fellow of the American Academy of Arts and Sciences (2003).
Legacy
Korsmeyer's work on apoptosis has had lasting impact on cancer research, leading to the development of Bcl-2–targeted drugs such as venetoclax. His research contributed to the broader understanding of how dysregulated cell death contributes to oncogenesis and treatment resistance.
Personal
Korsmeyer died of pancreatic cancer at the age of 54 in Houston, Texas. His contributions continue to influence ongoing research into cell death pathways and therapeutic strategies.
